Table 1 Basal characteristics stratified by serum C3.
From: Role of serum complement C3 and C4 on kidney outcomes in IgA nephropathy
High ≥ 140 N = 14 | Medium 90 -140 N = 72 | Low ≤ 90 N = 15 | Overall N = 101 | p-value* | |
|---|---|---|---|---|---|
Male gender, n (%) | 12 (85.7%) | 46 (63.9%) | 8 (53.3%) | 66 (65.3%) | 0.185 |
Age at biopsy years (± SD) | 46.29 (9.45) | 41.15 (14.44) | 46.13 (13.01) | 42.60 (13.73) | 0.249 |
Hypertension, n (%) | 12 (85.7%) | 37 (51.4%) | 11 (73.3%) | 60 (59.4%) | 0.028 |
SBP, mmHg (± SD) | 133.57 (14.99) | 122.83 (16.15) | 129.00 (14.04) | 125.26 (16.06) | 0.044 |
DBP, mmHg (± SD) | 80.71 (9.17) | 76.79 (11.08) | 79.33 (8.84) | 77.72 (10.54) | 0.365 |
Diabetes, n (%) | 3 (21.4%) | 3 (4.2%) | 1 (6.7%) | 7 (6.9%) | 0.04 |
CVD, n (%) | 3 (21.4%) | 7 (9.7%) | 3 (20.0%) | 13 (12.9%) | 0.324 |
Smoke, n (%) | |||||
Ex | 2 (14.3%) | 3 (4.2%) | 1 (6.7%) | 6 (5.9%) | 0.396 |
Current | 2 (14.3%) | 7 (9.7%) | 2 (13.3%) | 11 (10.9%) | |
eGFR, mL/min/1.73 m2 (± SD) | 68.64 (23.96) | 75.67 (36.17) | 47.00 (31.81) | 70.44 (35.33) | 0.015 |
uProt, g/24 h [IQR] | 1.81 [1.15, 4.10] | 0.75 [0.30, 1.60] | 1.46 [0.88, 3.18] | 1.04 [0.38, 1.90] | 0.004 |
Tot. protein, g/L (± SD) | 6.91 (1.23) | 6.72 (0.68) | 6.41 (0.91) | 6.70 (0.78) | 0.437 |
Albumin, g/L (± SD) | 3.98 (0.84) | 3.95 (0.70) | 3.59 (0.72) | 3.91 (0.72) | 0.410 |
C4, mg/dL (± SD) | 40.71 (8.65) | 33.56 (9.48) | 27.40 (10.64) | 33.63 (10.11) | 0.001 |
IgG, mg/dL (± SD) | 1086.36 (325.43) | 985.40 (267.29) | 956.20 (363.41) | 995.45 (291.51) | 0.429 |
IgA, mg/dL [IQR] | 263.50 [220.50, 460.25] | 302.00 [236.00, 371.00] | 273.00 [217.50, 411.00] | 294.00 [229.75, 377.75] | 0.975 |
IgM, mg/dL (± SD) | 86.43 (38.67) | 100.49 (43.30) | 119.33 (65.64) | 101.39 (47.19) | 0.166 |
CD4/CD8 ratio (± SD) | 1.74 (0.64) | 1.72 (0.60) | 1.78 (0.52) | 1.73 (0.59) | 0.907 |
Immunosuppression, n (%) | 12 (85.7%) | 49 (68.1%) | 11 (73.3%) | 72 (71.3%) | 0.479 |
Composite renal outcome, n (%) | 1 (7.1%) | 6 (9.2%) | 5 (33.3%) | 12 (12.8%) | 0.015 |
Time to outcome months (± SD) | 54.28 (13.08) | 45.57 (34.04.) | 27.53 (19.34) | 43.86 (30.75) | 0.040 |
